Our Products

Code name	International Nonproprietary Name	Therapeutic Area (Main Indications)	Status
FKB327	Adalimumab （Fully-Human Anti-TNF-α Monoclonal Antibody）	Immunology (Rheumatoid Arthritis, Psoriasis, Crohn's Disease)	Launched in EU Countries in 2018（Hulio^Ⓡ）
FKB238	Bevacizumab （Humanized Anti-VEGF Monoclonal Antibody）	Oncology (Colorectal Cancer, Non- Small Cell Lung Cancer, Cervical Cancer)	In Development